Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Seaport Therapeutics, Inc. Common Stock

SPTX

Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.

Last trade $18.12
Day change -$1.005 (-5.26%)
Day range $18.06 – $20.03
Volume 187,776
Market cap $1.02B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.02B
Price / earnings
—
Price / book
2.58×
Price / sales
—
EV / sales
—
EV / EBITDA
-7.78×

Profitability

Earnings per share
-$2.14
Return on assets
-27.39%
Return on equity
-28.78%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
17.48×
Quick ratio
17.48×
Cash ratio
3.6×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$84.77M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SPTX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026
Revenue$0$0
Cost of revenue$0$0
Gross profit$0$0
Selling, general and administrative$6.45M$41.19M
Research and development$23.89M$24.62M
Total operating expenses$30.35M$65.81M
Operating income-$30.35M-$65.81M
Interest expense$0$0
Income before taxes-$26.27M-$62.35M
Income taxes$127K$251K
Net income-$26.39M-$62.6M
Net income attributable to common shareholders-$26.39M-$62.6M
EBITDA-$30.32M-$65.78M
Basic earnings per share-$0.49-$1.78
Diluted earnings per share-$0.49-$1.78

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

How Much Upside is Left in Seaport Therapeutics, Inc (SPTX)? Wall Street Analysts Think 77.91%

Seaport Therapeutics (SPTX) closed at $20.96 with a mean analyst price target of $37.29, suggesting 77.9% upside potential. The stock has gained 16.9% over the past four weeks. Analysts have revised earnings estimates higher, and SPTX holds a Zacks Rank #2 (Buy) rating, indicating strong near-term upside potential despite cautions about relying solely on price targets.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.